Corporate
A proud year: Looking back on 2022
As we approach the end of the year, it’s only natural to reflect on the previous 12 months, whether from
December 27, 2022
As we approach the end of the year, it’s only natural to reflect on the previous 12 months, whether from
Keeping the patient at the heart of our research: My take-homes from speaking at the C3 Summit discussing inclusivity and
SmallPharma, a biotechnology company focused on short-acting psychedelic-assisted therapies for mental health conditions has enlisted MAC to support a new
At MAC, we have a proud history of establishing one of the UK’s first ever memory clinics back in 1988.
The Transatlantic Growth campaign (TAG) is an annual campaign that highlights and celebrates businesses that demonstrate growth and investment on
To continue to meet the research needs of our clients and their patients across the globe, MAC Clinical Research has
Initiator Pharma A/S, a clinical-stage biotech company that is developing a novel treatment of erectile dysfunction (ED), today announced statistically significant results on key efficacy endpoints in severe ED patients after a single administration of IPED2015. Moreover, no observations of critical adverse events were recorded.
October 24, 2018 MANCHESTER, ENGLAND Across every clinical trial, Pharma and Biotech have a dire need to access patients in efficient
MAC Neuroscience Centre of excellence, the early phase division of MAC Clinical Research, has been awarded Accreditation from the Medicines and Healthcare products Regulatory Agency (MHRA).
We are delighted to welcome Dr John Connell to MAC who will lead our pharmacodynamic offering. Dr Connell completed his
Follow MAC Clinical Research on social media to keep up to date with our latest news and updates.
